1. Home
  2. NMG vs IRWD Comparison

NMG vs IRWD Comparison

Compare NMG & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nouveau Monde Graphite Inc.

NMG

Nouveau Monde Graphite Inc.

HOLD

Current Price

$1.91

Market Cap

671.4M

ML Signal

HOLD

Logo Ironwood Pharmaceuticals Inc.

IRWD

Ironwood Pharmaceuticals Inc.

HOLD

Current Price

$3.58

Market Cap

663.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NMG
IRWD
Founded
2011
1998
Country
Canada
United States
Employees
N/A
N/A
Industry
Other Metals and Minerals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
671.4M
663.6M
IPO Year
2015
2009

Fundamental Metrics

Financial Performance
Metric
NMG
IRWD
Price
$1.91
$3.58
Analyst Decision
Strong Buy
Buy
Analyst Count
2
3
Target Price
$5.75
$7.67
AVG Volume (30 Days)
946.2K
2.2M
Earning Date
05-13-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
1400.00
EPS
N/A
0.24
Revenue
N/A
$298,276,000.00
Revenue This Year
N/A
$57.95
Revenue Next Year
N/A
$4.39
P/E Ratio
N/A
$15.23
Revenue Growth
N/A
8.88
52 Week Low
$1.60
$0.55
52 Week High
$6.06
$5.78

Technical Indicators

Market Signals
Indicator
NMG
IRWD
Relative Strength Index (RSI) 40.72 39.56
Support Level $1.81 $3.07
Resistance Level $2.00 $3.92
Average True Range (ATR) 0.11 0.33
MACD -0.02 -0.11
Stochastic Oscillator 25.56 7.45

Price Performance

Historical Comparison
NMG
IRWD

About NMG Nouveau Monde Graphite Inc.

Nouveau Monde Graphite Inc is a mineral exploration company. The company specializes in the exploration, evaluation, and development of mineral properties located in Quebec and is developing a natural graphite-based anode material that would qualify as battery-grade material to supply the lithium-ion industry. The Company currently operates in two segments: the Mining projects (which includes the Matawinie Mine project and the Uatnan Mining Project) and the Battery Material Plant project.

About IRWD Ironwood Pharmaceuticals Inc.

Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.

Share on Social Networks: